Roundtable (RT) selections published on 7/11/2025 listed 26 dividend picks for 2025. Click for more on Dividend Quick Picks & ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 ...

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 ...

This was the stock's second consecutive day of losses.

Becton, Dickinson (NYSE:BDX) declares $1.04/share quarterly dividend, in line with previous. Forward yield 2.29% Payable Sept. 30; for shareholders of record Sept. 8; ex-div Sept. 8. See BDX Dividend ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” second quarter 2025 investor letter. The fund ...

Any one of the majors will be thrilled to snap some of these brands because there’s very little organic growth in the ...

Waters Corporation announces a $17.5 billion acquisition of Becton Dickinson's bioscience unit, expanding its reach in ...

The selection of BD LibertasTM Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clini ...

According to Benzinga Pro, Becton Dickinson's peer group average for short interest as a percentage of float is 4.29%, which ...